抗真菌药物市场 - 按药物类别（唑类、棘白菌素）、适应症（念珠菌病、曲霉病）、感染类型（全身性、表浅性）、给药途径、药物、类型、配销通路和预测2024 - 2032

抗真菌药物市场规模预计从2024 年到2032 年将以3.7% 的复合年增长率扩大。等慢性病的患者中，正在加速抗霉菌药物的需求药物。

药物开发的重大创新，包括新型抗真菌药物和联合疗法的引入，正在提高这些药物的渗透率。例如，2024年1月，全球医疗保健公司Fresenius Kabi推出了泊沙康唑注射液，这是Noxafil(R)的仿製药替代品，用于治疗或预防免疫功能低下的成人和儿童的严重真菌感染。

新兴经济体老年人口的不断扩大、人们对真菌感染的认识不断提高以及医疗基础设施的改善，都进一步增强了产品的吸引力。抗真菌抗药性的日益普遍和新真菌菌株的出现进一步凸显了对创新治疗方案的需求，从而推动了抗真菌药物的研发投资。

整个产业分为药物类别、适应症、感染类型、给药途径、药物、类型、配销通路和地区。

就药物类别而言，2024年至2032年，多烯细分市场的市场规模预计将以2.9%的复合年增长率增长。感染方面的有效性。多烯针对多种真菌病原体的广谱活性和既定功效也有助于其继续用作一线治疗。

根据感染类型，预计到2032 年，表浅抗真菌感染领域的抗真菌药物市场复合年增长率将达到5.3%。外用抗真菌药物的需求药物。非处方抗真菌治疗的可用性以及人们对早期治疗重要性的认识不断提高也将推动该细分市场的成长。

从地区来看，从2024 年到2032 年，亚太地区抗真菌药物市场的复合年增长率预计将达到4.3%。不断扩大。人们对真菌疾病的认识不断提高，医疗保健服务的普及正在推动抗真菌药物的吸引力。新兴经济体越来越多地采用抗真菌药物以及对新药配方的大量投资将有利于区域产业的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 真菌感染盛行率增加
    • 抗真菌药物的认识和采用不断提高
    • 增加开发新型抗真菌药物的研发活动
  • 产业陷阱与挑战
    • 增加抗真菌药物抗药性
    • 增加产品召回
• 成长潜力分析
• 管道分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2018 - 2032 年

• 主要趋势
• 唑类
• 棘白菌素
• 多烯
• 烯丙胺
• 其他药物类别

第 6 章：市场估计与预测：按指标划分，2018 年 - 2032 年

• 主要趋势
• 皮癣菌病
• 曲菌病
• 念珠菌病
• 毛霉菌病
• 其他适应症

第 7 章：市场估计与预测：按感染类型，2018 年 - 2032 年

• 主要趋势
• 全身抗霉菌感染
• 表浅抗真菌感染

第 8 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 口服
• 专题
• 可注射

第 9 章：市场估计与预测：按药物分类，2018 年 - 2032 年

• 主要趋势
• 处方
• 场外交易

第 10 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• 品牌化
• 通用的

第 11 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 12 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 13 章：公司简介

• Abbott Laboratories
• Astellas Pharma, Inc.
• Bayer AG
• Enzon Pharmaceuticals, Inc.
• GlaxoSmithKline plc
• Glenmark
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi

Antifungal Drugs Market size is projected to expand at 3.7% CAGR from 2024 to 2032. The increasing incidence of fungal infections, particularly among immunocompromised patients and those with chronic conditions, such as HIV/AIDS, cancer, and diabetes is accelerating the demand for antifungal medications.

Significant innovations in drug development, including the introduction of novel antifungal agents and combination therapies are increasing the penetration of these drugs. For instance, in January 2024, Fresenius Kabi, a global healthcare company, launched Posaconazole Injection, a generic alternative to Noxafil(R), for the treatment or prevention of severe fungal infections in immunocompromised adults and children.

The expanding geriatric population, rising awareness about fungal infections, and improving healthcare infrastructure in emerging economies are further accelerating the product appeal. The growing prevalence of antifungal resistance and the emergence of new fungal strains is further underscoring the need for innovative treatment options, driving R&D investments in antifungal drugs.

The overall industry is segregated into drug class, indication, infection type, route of administration, medication, type, distribution channel, and region.

In terms of drug class, the market size from the polyenes segment is estimated to rise at 2.9% CAGR from 2024 to 2032. This is due to the effectiveness of polyene drugs, such as amphotericin B in treating severe and systemic fungal infections. The broad-spectrum activity and established efficacy of polyenes against a wide range of fungal pathogens is also contributing to their continued use as first-line treatments.

Based on infection type, the antifungal drugs market from the superficial antifungal infections segment is anticipated to expand at 5.3% CAGR through 2032. The increasing prevalence of superficial fungal infections like athlete's foot, ringworm, and fungal nail infections is driving the demand for topical antifungal medications. The availability of OTC antifungal treatments and the rising awareness about the importance of early treatment will also drive the segment growth.

Regionally, the Asia Pacific antifungal drugs market is estimated to expand at 4.3% CAGR from 2024 to 2032. This can be credited to the large and growing population, increasing incidence of fungal infections, and expanding healthcare infrastructure. The rising awareness about fungal diseases and improving access to healthcare services is driving the appeal of antifungal drugs. The growing adoption of antifungal medications in emerging economies and hefty investments in the formulation of new drugs will favor the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of fungal infections
    • 3.2.1.2 Rising awareness and adoption of antifungal drugs
    • 3.2.1.3 Increasing R&D activities for developing novel antifungal drugs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Increasing antifungal drug resistance
    • 3.2.2.2 Increasing product recalls
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Azoles
• 5.3 Echinocandins
• 5.4 Polyenes
• 5.5 Allylamines
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Dermatophytosis
• 6.3 Aspergillosis
• 6.4 Candidiasis
• 6.5 Mucormycosis
• 6.6 Other indications

Chapter 7 Market Estimates and Forecast, By Infection Type, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Systemic antifungal infections
• 7.3 Superficial antifungal infections

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Topical
• 8.4 Injectable

Chapter 9 Market Estimates and Forecast, By Medication, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Prescription
• 9.3 OTC

Chapter 10 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Branded
• 10.3 Generic

Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 Hospital pharmacies
• 11.3 Retail pharmacies
• 11.4 Online pharmacies

Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Rest of Europe
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 Japan
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 Rest of Asia Pacific
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Rest of Latin America
• 12.6 Middle East and Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 Rest of Middle East and Africa

Chapter 13 Company Profiles

• 13.1 Abbott Laboratories
• 13.2 Astellas Pharma, Inc.
• 13.3 Bayer AG
• 13.4 Enzon Pharmaceuticals, Inc.
• 13.5 GlaxoSmithKline plc
• 13.6 Glenmark
• 13.7 Merck & Co., Inc.
• 13.8 Novartis AG
• 13.9 Pfizer, Inc.
• 13.10 Sanofi